Nordic Nanovector on track to start PARADIGME

Second quarter report shows continued solid operational progress.
August 23, 2017/by Elisabeth K. Andersen

Vi er på Arendalsuka

Jónas Einarsson, administrerende direktør i Radiumhospitalets…
August 14, 2017/by Elisabeth K. Andersen

Nordic Nanovector: Results from first quarter 2017

Our portfolio company Nordic Nanovector shows  continued progress…
May 24, 2017/by radforsk

Photocure: Results for the first quarter 2017

Our portfolio company Photocure reported a Hexvix/Cysview revenue…
May 24, 2017/by radforsk

Targovax ASA: First quarter 2017 results

Targovax is a clinical stage company focused on developing immuno-oncology…
April 25, 2017/by radforsk

OncoImmunity wins prestigious EU grant

OncoImmunity AS was ranked fourth out of 250 applicants for the…
April 19, 2017/by radforsk

Targovax ASA: Fourth quarter and full year 2016 results

Our portfolio company Targovax ASA has announced its fourth quarter and full year 2016 results.
February 16, 2017/by radforsk

Photcure with full year report

Radforsk porfolio company Photocure reported a revenue growth of 10 % to NOK 38.1 million in the fourth quarter of 2016.
February 15, 2017/by radforsk

Oncoinvent closes $ 25 Million Private Placement

Our portfolio company Oncoinvent announced today the closing…
February 9, 2017/by radforsk

PCI Biotech awarded NOK 13.8 million from The Research Council of Norway

Our portfolio company PCI Biotech has been granted NOK 13.8 million…
January 27, 2017/by radforsk

Oncoimmunity granted NOK 300,000 from Innovation Norway

The grant will be used to develop a software framework to predict the peptides that confer maximum immunogenicity with minimum autoimmune side-affects to a patient.
January 17, 2017/by radforsk

PCI Biotech and Ultimovacs awarded NOK 500,000 from Innovation Norway

The grant will be used to further development of the existing preclinical research collaboration of the two companies.
January 9, 2017/by radforsk